Vickie & Jack Farber
Vision Research Center
RESEARCH_Secondary Page Header
CURRENT RETINA CLINICAL TRIALS
Wills Eye Retina specialists are in the forefront of research efforts, participating in multiple clinical trials to investigate new forms of treatment for macular degeneration, diabetic retinopathy, and a variety of other retinal conditions. We are committed to providing access to new treatments and have been the principal investigators of most of the major clinical trials in retina. For several, we are the only center involved nationwide.
For more information about
Retina Clinical Trials,
call 215-928-3092
NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION
4DMT FRONT1
A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection of 4D-150 in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration (4FRONT-1)
Learn more.
Adverum
A Multi-Center, Randomized, Double-Masked, Active-Comparator-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Ixoberogene soroparvovec (Ixo-vec) in Participants with Neovascular Age-Related Macular Degeneration
Learn more.
Alcon NOVA1
A Phase 1/2 Two-Stage Dose Escalation and Randomized Parallel Group Study to Evaluate the Safety, Preliminary Treatment Effects, and Durability of AR-14034 Sustained Release Implant Compared to Intravitreal Anti-Vascular Endothelial Growth Factor Treatment in Participants with Neovascular Age-Related Macular Degeneration (NOVA-1)
Learn more.
DRCR Protocol AO
Home OCT-Guided Treatment versus Treat and Extend for the Management of 1 Neovascular AMD (Protocol AO)
Learn more.
Eyepoint (LUCIA)
A Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects with Wet AMD
Learn more.
REGENXBIO AAVIATE
A Phase 2, Randomized, Dose-escalation, Ranibizumab-controlled
Study to Evaluate the Efficacy, Safety, and Tolerability of RGX-314 Gene Therapy Delivered via One or Two Suprachoroidal Space (SCS) Injections in Participants with Neovascular Age-Related Macular Degeneration (nAMD) (AAVIATE)
Learn more.
RegenxBio ASCENT
A Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD (ASCENT)
Learn more.
RegenxBio ATMOSPHERE
A Randomized, Partially Masked, Controlled, Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD (ATMOSPHERE)
Learn more.
Roche/Genentech BURGUNDY
A THREE-PART, PHASE I STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF RO7250284 FOLLOWING INTRAVITREAL ADMINISTRATION OF MULTIPLE ASCENDING DOSES AND SUSTAINED DELIVERY FROM THE PORT DELIVERY SYSTEM IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (BURGUNDY)
Learn more.
Sanofi
A Phase 1/2 dose escalation and dose expansion study to evaluate the safety, tolerability, and efficacy of one-time intravitreal dose of SAR402663 in participants with neovascular age-related macular degeneration
Learn more.
Vanotech
A Phase I, Open-label, Multicenter, Dose-Escalating Study to Evaluate the Safety and Tolerability of KH631 Gene Therapy in Participants with Neovascular Age-related Macular Degeneration.
Learn more.
DIABETIC EYE DISEASE CLINICAL TRIALS
EyeBiotech BRUNELLO
A RANDOMIZED, DOUBLE-MASKED, MULTI-CENTER, 3-ARM PIVOTAL PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRAVITREAL EYE103 COMPARED WITH INTRAVITREAL RANIBIZUMAB (0.5MG) IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA
Learn more.
Genentech
A PHASE I, MULTIPART, MULTICENTER STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF RO7497372 FOLLOWING INTRAVITREAL ADMINISTRATION IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA (PART 1 NON-RANDOMIZED, OPEN-LABEL, MULTIPLE ASCENDING DOSE; PART 2 RANDOMIZED, DOUBLE-MASKED).
Learn more.
Genentech THAMES GR43828
A PHASE I/II STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF RO7446603 ADMINISTERED ALONE OR IN COMBINATION WITH AFLIBERCEPT OR FARICIMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA.
Learn more.
Kyowa Kirin 4951-003
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients with Diabetic Macular Edema.
Learn more.
For more information about
Retina Clinical Trials,
call 215-928-3092
GEOGRAPHIC ATROPHY CLINICAL TRIALS
ANX007 GA_002 (PPD)
A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients with Geographic Atrophy (GA).
Learn more.
Apellis GARLAND
A PROSPECTIVE, MULTICENTER, OPEN-LABEL, OBSERVATIONAL PHASE 4 STUDY TO EVALUATE REAL-WORLD SAFETY, TOLERABILITY, AND TREATMENT PATTERNS OF PEGCETACOPLAN (SYFOVRE) IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION.
Learn more.
Astellas (AIRM)
A Phase 1b, Multicenter, Dose Escalation, Evaluation of Safety and Tolerability of ASP7317 for Geographic Atrophy Secondary to Age-related Macular Degeneration
Learn more.
Belite Bio PHOENIX
Phase 3, Multicenter, RandOmized, Double-masked, PlacEbo-CoNtrolled Study of TInlarebant to EXplore Safety and Efficacy in the Treatment of Geographic Atrophy (the PHOENIX Study).
Learn more.
Boehringer Ingelheim JADE
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebocontrolled, dose-finding study to evaluate the efficacy and safety of BI 1584862.
Learn more.
Boehringer Ingelheim VERDAnT
Randomized, double-masked, active-controlled, multi-center study to evaluate efficacy and safety of two regimens of intravitreal BI771716 against pegcetacoplan in participants with geographic atrophy secondary to age-related macular degeneration (VERDANT Trial).
Learn more.
Lineage/Genentech GR44251 JUMPER
A PHASE IIA MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO OPTIMIZE SUBRETINAL SURGICAL DELIVERY AND TO EVALUATE SAFETY AND ACTIVITY OF OPREGEN IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION.
Learn more.
Regeneron (R3918-AMD-2326) SIENA
MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PLACEBO-CONTROLLED PHASE 3 STUDY OF THE EFFICACY, SAFETY, AND TOLERABILITY OF SUBCUTANEOUSLY ADMINISTERED POZELIMAB IN COMBINATION WITH CEMDISIRAN OR CEMDISIRAN ALONE IN PARTICIPANTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION.
Learn more.
Stealth Biotherapeutics RENEW
ReNEW: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects who have Dry Age-Related Macular Degeneration (Dry AMD).
Not available yet
RETINITIS PIGMENTOSA CLINICAL TRIALS
AGTC Beacon
A Randomized, Controlled, Masked, Multi-center Study Evaluating the Efficacy, Safety, and Tolerability of Two Doses of AGTC-501 Compared to an Untreated Control Group in Male Participants with X-linked Retinitis Pigmentosa.
Learn more.
STARGARDT DISEASE CLINICAL TRIALS
Belite Bio DRAGON
A Phase 1b Open-label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Tinlarebant in Japanese Subjects with Stargardt Disease and a Phase 2/3 Randomized, Double-masked, and Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Tinlarebant in Subjects with Stargardt Disease.
Learn more.
UVEITIS CLINICAL TRIALS
Priovant CLARITY PVT-2201-303
A Phase 3 Randomized, Double-Masked, Placebo-Controlled Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults with Active, Non-Infectious Intermediate-, Posterior-, and Panuveitis.
Learn more.